Jun 24, 2023, 18:25
Still no role for targeting PI3K pathway in mCRPC – Arun Azad
Now online Clinical Cancer Research- Phase IB study ipatasertib plus ipatasertib in mCR prostate cancer post-NHA. No evidence of synergistic or additive antitumor activity. No clear signal of benefit in biomarker +ve populations either.
My take: Still no role for targeting PI3K pathway in mCRPC
Source: Arun Azad/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43
Nov 12, 2024, 19:34